PQK7

PQK7 (2.5-70 μM; 7-32 h) inhibits α-Syn fibril formation, reduces ThT fluorescence by approximately 40% after 30 h, and exhibits sustained inhibitory activity over time, but does not disrupt pre-formed fibrils^[1].
PQK7 (2-20 μM; 24 h) reduces β-sheet formation of α-Syn monomers and induces the transition of this protein to a random coil conformation^[1].
PQK7 (2.5 μM; 0-48 h) reduces the number and size of α-Syn aggregates^[1].
PQK7 (2.5 μM; 12-32 h) maintains α-Syn in a soluble state during the fibrosis process^[1].
PQK7 (2.5-70 μM; ~48 h) reduces the seeding activity of α-Syn fibrillation products; additionally, at concentrations of 2.5-30 μM for 30 h, it inhibits preformed fibril-induced secondary α-Syn fibrillation^[1].
PQK7 (2 μM; 24 h) reduces the nucleation of α-Syn monomers on preformed α-Syn fibrils^[1].
PQK7 (2 μM; 24 h) reduces α-Syn aggregate-induced cytotoxicity in SH-SY5Y cells and restores cell viability after 24 h of treatment^[1].
PQK7 (2 μM; 36 h fibril formation, 24 h cell treatment) restores normal cell cycle progression in SH-SY5Y cells treated with 36 h-aged α-Syn fibrils, reverses the decrease in the proportion of G1-phase cells, and reduces the proportion of cells entering the apoptotic sub-G1 phase after 24 h of treatment^[1].
PQK7 (2-70 μM; 6 h) reduces intracellular ROS levels induced by α-Syn aggregates in SH-SY5Y cells^[1].
PQK7 (2 μM; 36 h fibril formation, 24 h cell treatment) significantly reduces late apoptosis and necrosis induced by α-Syn fibril treatment for 24 h in SH-SY5Y cells, while slightly increasing the level of early apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.